KAPA — Kairos Pharma, LTD.

—
NYSE · Health Care · Pharmaceuticals · CIK 1962011 ·
Last close
$0.40
Market Cap
$1.35M
52W High
$7.28
52W Low
$0.38
ADV30
345,537
Next earnings
—
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company's products under the preclinical stage include KROS 201 that activates T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist designed to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, as well as a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions for the treatment of autoimmune disease; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor that targets tumor cells in RelA/p65 biomarker-positive solid tumors for the treatment of triple-negative breast cancer; KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13, reversing tumor associated macrophage inhibition that blocks the IL4/IL13 cytokine immune receptors for the treatment of triple-negative breast cancer; and ENV 205, an antibody fragment that targets mitochondrial DNA for the treatment of prostate cancer. The company also develops ENV-105 (carotuximab). The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -2,009,000 -1,984,000 4,370,000 3,125,000 495,000
Jun 2026 0 — -1,417,000 -1,388,000 4,456,000 2,626,000 265,000
Mar 2026 0 — -1,690,000 -1,654,000 5,744,000 3,675,000 431,000
Dec 2025 0 — -1,415,000 -1,365,000 6,540,000 4,491,000 199,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-3,970,000
Investing CF
—
Financing CF
$3,562,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.29
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-17,304,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-5,870,000
Pretax Income TTM
$-5,805,000
Interest Exp TTM
$0
Analysts
2

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -5,572,000 -5,447,000 6,540,000 199,000 6,341,000 -3,441,000
Dec 2024 0 -2,343,000 -2,603,000 5,768,000 992,000 4,776,000 -3,955,000
Dec 2023 0 -1,714,000 -1,812,000 965,000 3,043,000 -2,078,000 81,000
Dec 2022 0 -571,000 -1,050,000 1,036,000 2,215,000 -1,179,000 -353,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-5,805,000
OpCashFlow TTM
—
Assets (Latest)
$4,456,000
Forward EPS
$-4.69

Peers — same industry

TickerNameMarket CapLastDaily %
GNPX Genprex, Inc. $1.37M $1.67 —
AGNPF Grey Matters Health Inc. $1.30M $0.24 —
CPMD CANNAPHARMARX, INC. $1.42M $0.00 —
HCWB HCW Biologics Inc. $1.43M $0.78 —
ISCO International Stem Cell CORP $1.28M $0.16 —

News headlines (Yahoo Finance, 1h cache)

Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
2026-11-05 14:15 · Yahoo
Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
2026-11-03 16:45 · Yahoo
CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma
2026-10-22 13:16 · Yahoo
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
2026-10-06 11:30 · Yahoo
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
2026-09-23 12:00 · Yahoo
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-09 12:00 · Yahoo
Kairos Pharma Announces 1-for-7 Reverse Stock Split
2026-08-21 20:30 · Yahoo
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
2026-07-22 12:35 · Yahoo
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever
2026-07-15 12:39 · Yahoo
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
2026-05-13 09:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.